Compounds that inhibit p38 MAPK protein, and methods of using the same, are provided for treating or preventing diseases such as cancer or inflammatory diseases.

The present invention relates to compounds and composition for inhibition of FASN, their synthesis, applications, and antidotes. An illustrative compound of the invention is shown below: ##STR00001##

Reinforcing bars include load transfer connectors. A link plate includes openings that mate with the load transfer connectors to overlie the splice between reinforcing bars being spliced. A cover plate may be fastened over the link plate.

Reinforcing bars include load transfer connectors. A link plate includes openings that mate with the load transfer connectors to overlie the splice between reinforcing bars being spliced. A cover plate may be fastened over the link plate.

The present invention relates to a process for the N-alkylation of amines by reacting an amine with an orthocarboxylic acid ester and with hydrogen in the presence of a hydrogenation catalyst.

Compounds of general formula IA, IB and IC outlined below, including pharmaceutically acceptable salts, solvates and hydrates thereof. Such compounds and pharmaceutical compositions comprising them may be used in medical conditions involving Ran GTPase.

##STR00001##

The present invention relates to a process for the N-alkylation of amines by reacting an amine with an orthocarboxylic acid ester and with hydrogen in the presence of a hydrogenation catalyst.

A process is provided for manufacturing a cyclic urea adduct of an ethyleneamine compound, the ethyleneamine compound having a linear NHCH.sub.2CH.sub.2NH group. The process includes, in an absorption step, contacting a liquid medium comprising an ethyleneamine compound having a linear NHCH.sub.2CH.sub.2NH group with a CO.sub.2-containing gas stream at a pressure of from about 1 to about 20 bara, resulting in the formation of a liquid medium into which CO.sub.2 has been absorbed. The process further includes bringing the liquid medium to cyclic urea formation conditions, and, in an urea formation step, forming cyclic urea adduct of the ethyleneamine compound, urea formation conditions including a temperature of at least about 120 C., wherein the total pressure at the end of the urea formation step is at most about 20 bara, and wherein the temperature in the absorption step is lower than the temperature in the urea formation step.

A process is provided for manufacturing a cyclic urea adduct of an ethyleneamine compound, the ethyleneamine compound having a linear NHCH.sub.2CH.sub.2NH group. The process includes, in an absorption step, contacting a liquid medium comprising an ethyleneamine compound having a linear NHCH.sub.2CH.sub.2NH group with a CO.sub.2-containing gas stream at a pressure of from about 1 to about 20 bara, resulting in the formation of a liquid medium into which CO.sub.2 has been absorbed. The process further includes bringing the liquid medium to cyclic urea formation conditions, and, in an urea formation step, forming cyclic urea adduct of the ethyleneamine compound, urea formation conditions including a temperature of at least about 120 C., wherein the total pressure at the end of the urea formation step is at most about 20 bara, and wherein the temperature in the absorption step is lower than the temperature in the urea formation step.

A lipid membrane structure includes, as lipid components, a lipid compound represented by Formula (I):

(R.sup.1)(R.sup.2)C(OH)(CH.sub.3).sub.a(OCO).sub.bX(I) [in the formula, a represents an integer of 3 to 5; b represents an integer of 0 or 1; R.sup.1 and R.sup.2 each independently represents a linear hydrocarbon group that may have COO; and X represents a 5- to 7-membered non-aromatic heterocyclic group or a group represented by Formula (B) (in the formula, d represents an integer of 0 to 3, and R.sup.3 and R.sup.4 each independently represents a C.sub.1-4 alkyl group or a C.sub.2-4 alkenyl group, where, R.sup.3 and R.sup.4 may be bonded to each other to form a 5- to 7-membered non-aromatic heterocycle (where, one or two C.sub.1-4 alkyl groups or C.sub.2-4 alkenyl groups may be substituted on the ring)].